$ALLO
Allogene Therapeutics, Inc. Stock $allo

$allo Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000173728720000047 Filed on August 05, 2020

Income Statement

Concept	2020 Q2	2019 Q2	2019 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$15.86M	$14.19M	$13.06M
YoY Change	11.77%	32.25%	402.31%
% of Gross Profit
Research & Development	$47.30M	$31.77M	$23.40M
YoY Change	48.85%	-74.06%
% of Gross Profit
Depreciation & Amortization	$1.890M	$1.150M	$544.0K
YoY Change	64.35%	155.56%
% of Gross Profit
Operating Expenses	$63.16M	$45.96M	$36.46M
YoY Change	37.42%	-65.96%	1303.97%
Operating Profit	-$63.16M	-$45.96M	-$36.46M
YoY Change	37.42%	-65.96%	1303.97%
Interest Expense	$2.340M	$4.560M	$4.830M
YoY Change	-48.68%	4045.45%
% of Operating Profit
Other Income/Expense, Net	$2.184M	$4.559M	$4.825M
YoY Change	-52.09%	4044.55%
Pretax Income	-$60.97M	-$41.40M	-$31.64M
YoY Change	47.27%	-69.31%	1116.77%
Income Tax	$0.00	-$200.0K	-$100.0K
% Of Pretax Income
Net Earnings	-$60.97M	-$41.24M	-$31.59M
YoY Change	47.84%	-69.43%	1116.25%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.53
Diluted Earnings Per Share	-$0.53	-$413.0K	-$324.6K
COMMON SHARES
Basic Shares Outstanding	115.4M shares		121.5M
Diluted Shares Outstanding	115.4M shares

Balance Sheet

Concept	2020 Q2	2019 Q2	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$899.7M	$502.4M	$470.4M
YoY Change	79.06%	249.15%
Cash & Equivalents	$280.4M	$112.6M	$97.05M
Short-Term Investments	$619.3M	$389.8M	$373.4M
Other Short-Term Assets	$9.900M	$5.800M	$10.50M
YoY Change	70.69%	1833.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$909.6M	$511.5M	$476.6M
YoY Change	77.81%	254.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$84.61M	$35.82M	$20.43M
YoY Change	136.21%	923.34%
Goodwill
YoY Change
Intangibles	$0.00	$452.0K	$603.0K
YoY Change	-100.0%
Long-Term Investments	$215.5M	$147.8M	$214.6M
YoY Change	45.81%
Other Assets	$2.160M	$2.238M	$432.0K
YoY Change	-3.49%
Total Long-Term Assets	$349.0M	$222.5M	$272.7M
YoY Change	56.87%	4843.44%
TOTAL ASSETS
Total Short-Term Assets	$909.6M	$511.5M	$476.6M
Total Long-Term Assets	$349.0M	$222.5M	$272.7M
Total Assets	$1.259B	$734.0M	$749.4M
YoY Change	71.46%	393.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.057M	$23.50M	$12.98M
YoY Change	-61.46%	1707.92%
Accrued Expenses	$31.80M	$14.50M	$14.30M
YoY Change	119.31%	7.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$40.90M	$38.00M	$27.27M
YoY Change	7.62%	158.5%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.163M	$5.495M	$6.065M
YoY Change	-42.44%	119.8%
Total Long-Term Liabilities	$3.163M	$5.495M	$6.065M
YoY Change	-42.44%	119.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$40.90M	$38.00M	$27.27M
Total Long-Term Liabilities	$3.163M	$5.495M	$6.065M
Total Liabilities	$95.13M	$78.36M	$68.14M
YoY Change	21.39%	355.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$511.6M	-$284.4M	-$243.1M
YoY Change	79.91%
Common Stock	$1.673B	$937.8M	$922.9M
YoY Change	78.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.163B	$655.6M	$681.2M
YoY Change
Total Liabilities & Shareholders Equity	$1.259B	$734.0M	$749.4M
YoY Change	71.46%	393.28%

Cashflow Statement

Concept	2020 Q2	2019 Q2	2019 Q1
OPERATING ACTIVITIES
Net Income	-$60.97M	-$41.24M	-$31.59M
YoY Change	47.84%	-69.43%	1116.25%
Depreciation, Depletion And Amortization	$1.890M	$1.150M	$544.0K
YoY Change	64.35%	155.56%
Cash From Operating Activities	-$26.72M	-$24.89M	-$30.26M
YoY Change	7.35%	311.4%	-605220.0%
INVESTING ACTIVITIES
Capital Expenditures	-$16.06M	-$7.860M	$10.42M
YoY Change	104.33%	1355.56%
Acquisitions
YoY Change
Other Investing Activities	-$412.9M	$52.35M	$43.31M
YoY Change	-888.77%	-2592.86%
Cash From Investing Activities	-$429.0M	$44.49M	$32.89M
YoY Change	-1064.19%	-1791.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	600.2M	240.0K	$684.0K
YoY Change	249970.83%	-99.84%
NET CHANGE
Cash From Operating Activities	-26.72M	-24.89M	-$30.26M
Cash From Investing Activities	-429.0M	44.49M	$32.89M
Cash From Financing Activities	600.2M	240.0K	$684.0K
Net Change In Cash	144.5M	19.84M	$3.316M
YoY Change	628.23%	-86.21%	66220.0%
FREE CASH FLOW
Cash From Operating Activities	-$26.72M	-$24.89M	-$30.26M
Capital Expenditures	-$16.06M	-$7.860M	$10.42M
Free Cash Flow	-$10.66M	-$17.03M	-$40.68M
YoY Change	-37.4%	209.07%	-813680.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001737287
	dei	Entity Central Index Key EntityCentralIndexKey	0001737287
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38693
	dei	Entity Registrant Name EntityRegistrantName	Allogene Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3562771
	dei	Entity Address Address Line1 EntityAddressAddressLine1	210 East Grand Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	457-2700
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	ALLO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	139291518	shares
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	280379000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	175126000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	619271000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	355407000	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9927000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14043000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	909577000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	544576000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	210794000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	58322000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42432000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	44495000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84605000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56449000	USD
CY2020Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	151000	USD
CY2020Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4299000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4299000	USD
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2160000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4618000	USD
CY2020Q2	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	4677000	USD
CY2019Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	4892000	USD
CY2020Q2	us-gaap	Assets Assets	1258544000	USD
CY2019Q4	us-gaap	Assets Assets	717802000	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	9057000	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51067000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9250000	USD
CY2020Q2	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	31838000	USD
CY2019Q4	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	23829000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	40895000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	33079000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51349000	USD
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3163000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4351000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	95125000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	88779000	USD
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	139233450	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	139233450	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	124267358	shares
CY2020Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1673026000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1023876000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-511576000	USD
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	124267358	shares
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	139000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	124000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-396122000	USD
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1830000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1145000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1163419000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	629023000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1258544000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	717802000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47296000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31774000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	89337000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	55177000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15862000	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14187000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31502000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27245000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	63158000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	45961000	USD
	us-gaap	Operating Expenses OperatingExpenses	120839000	USD
	us-gaap	Operating Expenses OperatingExpenses	82422000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-63158000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-45961000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-120839000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-82422000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2340000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4559000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5600000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9384000	USD
CY2020Q2	us-gaap	Other Expenses OtherExpenses	156000	USD
CY2019Q2	us-gaap	Other Expenses OtherExpenses	0	USD
	us-gaap	Other Expenses OtherExpenses	215000	USD
	us-gaap	Other Expenses OtherExpenses	0	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2184000	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4559000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5385000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9384000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-60974000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-41402000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-115454000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-73038000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-159000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-209000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-60974000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-41243000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-115454000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-72829000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	220000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	756000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	685000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1855000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60754000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40487000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-114769000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-70974000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.53
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.03
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.74
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	115377210	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	99846946	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112163123	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	98588410	shares
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	606519000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4476000	USD
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	710000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16770000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	595698000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-60974000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	220000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1163419000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	629023000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4780000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1419000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	30985000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1438000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-115454000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	685000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1163419000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	681228000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	237000	USD
CY2019Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3170000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11487000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-41243000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	756000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	655635000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	703164000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	237000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3170000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19354000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	684000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-72829000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1855000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	655635000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	521000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	30985000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	19354000	USD
	us-gaap	Profit Loss ProfitLoss	-115454000	USD
	us-gaap	Profit Loss ProfitLoss	-72829000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	151000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	301000	USD
	us-gaap	Depreciation Depreciation	3781000	USD
	us-gaap	Depreciation Depreciation	1543000	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-20000	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	2285000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1060000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1548000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-209000	USD
	allo	Income Loss From Cost Method Investment IncomeLossFromCostMethodInvestment	-215000	USD
	allo	Income Loss From Cost Method Investment IncomeLossFromCostMethodInvestment	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4116000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-2458000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1993000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-503000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1332000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	6829000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-107000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1188000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1282000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67530000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55148000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28307000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18279000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	4877000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	221633000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	197415000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	642181000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	101756000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-443978000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	77380000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	4780000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	236000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1438000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	684000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	616761000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	920000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	105253000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23152000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179425000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93731000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	284678000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	116883000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8298000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	13667000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14800000	USD
	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	2816000	USD
	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	1156000	USD
	allo	Cash Received For Amounts Related To Tenant Improvement Allowances CashReceivedForAmountsRelatedToTenantImprovementAllowances	1617000	USD
	allo	Cash Received For Amounts Related To Tenant Improvement Allowances CashReceivedForAmountsRelatedToTenantImprovementAllowances	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November 30, 2017, in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Public Offerings </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In November 2019, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen), under which the Company may from time to time issue and sell shares of its common stock through Cowen in at-the-market (ATM) offerings for an aggregate offering price of up to $250.0 million. The aggregate compensation payable to Cowen as the Company's sales agent equals up to 3.0% of the gross sales price of the shares sold through it pursuant to the sales agreement. In January 2020, the Company sold an aggregate of 570,839 shares of common stock in ATM offerings resulting in net proceeds of $14.8 million.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In June 2020, the Company sold 13,457,447 shares of its common stock, which included 1,755,319 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, in an underwritten public offering at a price of $47.00 per share, which resulted in gross proceeds of approximately $632.5 million. Net proceeds to the Company after deducting the underwriting discounts and commissions and other expenses were approximately $595.7 million.</span></div><div style="text-align:justify;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Need for Additional Capital</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company’s ultimate success depends on the outcome of its research and development activities. The Company had cash and cash equivalents and investments of $1.1 billion as of June 30, 2020. Since inception through June 30, 2020, the Company has incurred cumulative net losses of $511.6 million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC). </span></div>In March 2020, the World Health Organization declared the global novel coronavirus disease (COVID-19) outbreak a pandemic. The Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s results may be adversely affected.
CY2019Q4	allo	Stock Issuance Maximum Value StockIssuanceMaximumValue	250000000.0	USD
CY2019Q4	allo	Stock Issuance Maximum Compensation Due To Third Party Percent StockIssuanceMaximumCompensationDueToThirdPartyPercent	0.030
CY2020Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	570839	shares
CY2020Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	13457447	shares
CY2020Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	47.00
CY2020Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	632500000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	595700000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	1100000000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-511600000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></div>
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1084564000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2339000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	65000	USD
CY2020Q2	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	1086838000	USD
CY2020Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	256773000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	619271000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	210794000	USD
CY2020Q2	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	1086838000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	535042000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1595000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8000	USD
CY2019Q4	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	536629000	USD
CY2019Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	122900000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	355407000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	58322000	USD
CY2019Q4	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	536629000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P3Y
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	93858000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	61921000	USD
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9253000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5472000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84605000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	56449000	USD
CY2018Q3	allo	Area Of New Office Building AreaOfNewOfficeBuilding	68000	sqft
CY2018Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P127M
CY2018Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P7Y
CY2020Q2	us-gaap	Tenant Improvements TenantImprovements	5000000.0	USD
CY2018Q4	allo	Area Of New Office Building AreaOfNewOfficeBuilding	14943	sqft
CY2018Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P124M
CY2018Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P7Y
CY2018Q4	allo	Allowance For Tenant Improvements AllowanceForTenantImprovements	800000	USD
CY2020Q2	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	4300000	USD
CY2019Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	4300000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2395000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1679000	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51067000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51349000	USD
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	53462000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	53028000	USD
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1868000	USD
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1354000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	3736000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	2705000	USD
CY2020Q2	us-gaap	Variable Lease Cost VariableLeaseCost	399000	USD
CY2019Q2	us-gaap	Variable Lease Cost VariableLeaseCost	263000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	608000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	401000	USD
CY2020Q2	us-gaap	Lease Cost LeaseCost	2267000	USD
CY2019Q2	us-gaap	Lease Cost LeaseCost	1617000	USD
	us-gaap	Lease Cost LeaseCost	4344000	USD
	us-gaap	Lease Cost LeaseCost	3106000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	2800000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2846000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6813000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7927000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8178000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8440000	USD
CY2020Q2	allo	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	56294000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	90498000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	34311000	USD
CY2020Q2	allo	Allowance For Tenant Improvements AllowanceForTenantImprovements	2725000	USD
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	53462000	USD
CY2020Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0835
CY2020Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y4M24D
CY2020Q2	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	5600000	USD
	allo	Number Of Shares As Percentage Of Common Shares Outstanding NumberOfSharesAsPercentageOfCommonSharesOutstanding	0.05
CY2020Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12562263	shares
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16770000	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11487000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30985000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19354000	USD
CY2020Q2	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	2800000	USD
CY2019Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	2800000	USD
CY2020Q2	us-gaap	Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent	2500000	USD
CY2019Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent	3900000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26715950	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31176666	shares
CY2020Q2	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	5600000	USD

Files In Submission

Name	View Source	Status
0001737287-20-000047-index-headers.html	Edgar Link	pending
0001737287-20-000047-index.html	Edgar Link	pending
0001737287-20-000047.txt	Edgar Link	pending
0001737287-20-000047-xbrl.zip	Edgar Link	pending
allo-20200630.htm	Edgar Link	pending
allo-20200630.xsd	Edgar Link	pending
allo-20200630xex311.htm	Edgar Link	pending
allo-20200630xex312.htm	Edgar Link	pending
allo-20200630xex321.htm	Edgar Link	pending
allo-20200630xexx101.htm	Edgar Link	pending
allo-20200630_cal.xml	Edgar Link	unprocessable
allo-20200630_def.xml	Edgar Link	unprocessable
allo-20200630_htm.xml	Edgar Link	completed
allo-20200630_lab.xml	Edgar Link	unprocessable
allo-20200630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALLO
Allogene Therapeutics, Inc. Stock $allo

2020 Q2 Form 10-Q Financial Statement

#000173728720000047 Filed on August 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLO Allogene Therapeutics, Inc. Stock $allo

2020 Q2 Form 10-Q Financial Statement

#000173728720000047 Filed on August 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLO
Allogene Therapeutics, Inc. Stock $allo